This study was aimed at evaluating the solubility and solution stability of a cocrystal form of carbamazepine with cinnamic acid in the presence of sodium dodecyl sulfate (SDS) as surfactant and polyvinyl pyrrolidone K17 (PVP) as polymer in the aqueous medium. The solubilities of carbamazepine and cinnamic acid, as well as that of cocrystal, were evaluated in various media including phosphate buffer solution (PBS) (pH 6.8), SDS at 0.5 and 2% concentration, and PVP at 0.5, 1, and 2% concentration. Carbamazepine–cinnamic acid cocrystal was more soluble than carbamazepine alone in PBS. Solubility and solution stability of cocrystal were improved by PVP and SDS. At high SDS concentration (2%), solubility of cocrystal is less than carbamazepine because of preferential solubilization of the drug despite increase of solution stability. Thus, SDS and PVP significantly influence the solubility and solution stability of carbamazepine–cinnamic acid cocrystal, which should be taken into account in develo** cocrystal formulations.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-022-02726-8/MediaObjects/11094_2022_2726_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-022-02726-8/MediaObjects/11094_2022_2726_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-022-02726-8/MediaObjects/11094_2022_2726_Fig3_HTML.png)
Similar content being viewed by others
References
H. D. Williams, N. L. Trevaskis, S. A. Charman, et al., Pharmacol. Rev., 65, 315 – 499 (2013).
N. Blagden, M. de Matas, P. T. Gavan, et al., Adv. Drug Deliv. Rev., 59, 617 – 630 (2007).
A. Ainurofiq, R. Mauludin, D. Mudhakir, et al., Pharm. Sci., 26, 399 – 405 (2020).
S. Aitipamula, R. Banerjee, A. K. Bansal, et al., Cryst. Growth Des., 12, 2147 – 2152 (2012).
M. Karimi-Jafari, L. Padrela, G. M. Walker, et al., Cryst. Growth Des., 18, 6370 – 6387 (2018).
D. D. Gadade and S. S. Pekamwar, Adv. Pharm. Bull., 6, 479 – 494 (2016).
A. L. Grzesiak, M. Lang, K. Kim, et al., J. Pharm. Sci., 92, 2260 – 2271 (2003).
N. Bolourtchian, A. Nokhodchi, and R. Dinarvand, Daru, 9, 12 – 22 (2001).
R. Shete, B. Thorat, and P. Amin, Pharm. Sci., 28, 459 – 469 (2022).
M. B. Hickey, M. L. Peterson, L. A. Scoppettuolo, et al., Eur. J. Pharm. Biopharm., 67, 112 – 119 (2007).
S. L. Childs, N. Rodriguez-Hornedo, L. S. Reddy, et al., CrystEngComm, 10, 856 – 864 (2008).
Q. Fu, Y. Han, Y. F. **e, et al., J. Mol. Struct., 1168, 145 – 152 (2018).
S. Cherukuvada and T. N. Guru Row, Cryst. Growth Des., 14, 4187 – 4198 (2014).
S. Kudo and H. Takiyama, J. Chem. Eng. Data, 63, 451 – 458 (2018).
M. Ullah, I. Hussain, and C. C. Sun, Drug Dev. Ind. Pharm., 42, 969 – 976 (2016).
F. Zhou, J. Zhou, H. Zhang, et al., J. Drug Deliv. Sci. Technol., 54, (2019).
H. Yamashita and C. C. Sun, Pharm. Res., 35, 4 (2018).
H. Yamashita and C. C. Sun, Pharm. Res., 36, 90 (2019).
M. Maghsoodi and O. Narimanpour, Pharm. Sci., 26, 314 – 322 (2020).
M. Maghsoodi and F. Shahi, Pharm. Sci., 25, 331 – 337 (2019).
A. Alhalaweh, H. R. H. Ali, and S. P. Velaga, Cryst. Growth Des., 14, 643 – 648 (2014).
M. Li, N. Qiao, and K. Wang, Pharmaceutics, 5, 508 – 524 (2013).
M. Ullah, H. Ullah, G. Murtaza, et al., BioMed Res. Int., 2015 (2015).
A. Avdeef, Eur. J. Pharm. Sci., 110, 2 – 18 (2017).
F. Keramatnia, A. Shayanfar, and A. Jouyban, J. Pharm. Sci., 104, 2559 – 2565 (2015).
H. G. Moradiya, M. T. Islam, S. Halsey, et al., CrystEngComm, 16, 3573 – 3583 (2014).
A. Shayanfar, K. Asadpour-Zeynali, and A. Jouyban, J. Mol. Liq., 187, 171 – 176 (2013).
M. S. Jasani, D. P. Kale, I. P. Singh, et al., Mol. Pharm., 16, 151 – 164 (2019).
R. Thakuria, A. Delori, W. Jones, et al., Int. J. Pharm., 453, 101 – 125 (2013).
K. Asadpour-Zeynali and M. Bastami, Spectrochim. Acta Part A Mol. Biomol. Spectrosc., 75, 589 – 597 (2010).
K. Löbmann, R. Laitinen, H. Grohganz, et al., Mol. Pharm., 8, 1919 – 1928 (2011).
A. Shayanfar and A. Jouyban, Powder Technol., 262, 242 – 248 (2014).
J. P. Marcolongo and M. Mirenda, J. Chem. Educ., 88, 629 – 633 (2011).
M. N. Alizadeh, A. Shayanfar, and A. Jouyban, J. Mol. Liq., 268, 410 – 414 (2018).
P. Tran, Y. C. Pyo, D. H. Kim, et al., Pharmceutics, 11, (2019).
H. A. Garekani, F. Sadeghi, and A. Ghazi, Drug Dev. Ind. Pharm., 29, 173 – 179 (2003).
T. Loftsson, Int. J. Pharm., 531, 276 – 280 (2017).
D. J. Good and R. H. Nair, Cryst. Growth Des., 9, 2252 – 2264 (2009).
Z. Rahman, C. Agarabi, A. S. Zidan, et al., AAPS PharmSciTech, 12, 693 – 704 (2011).
A. Shayanfar, S. Velaga, and A. Jouyban, Fluid Phase Equilibria, 363, 97 – 105 (2014).
A. Alhalaweh, A. Sokolowski, N. Rodriguez-Hornedo, et al., Cryst. Growth Des., 11, 3923 – 3929 (2011).
M. P. Lipert and N. Rodriguez-Hornedo, Mol. Pharm., 12, 3535 – 3546 (2015).
A. Alvani, A. Jouyban, and A. Shayanfar, J. Mol. Liq., 281, 86 – 92 (2019).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sabouri, S., Shayanfar, A. Effects of Surfactant and Polymer on Thermodynamic Solubility and Solution Stability of Carbamazepine–Cinnamic Acid Cocrystal. Pharm Chem J 56, 913–917 (2022). https://doi.org/10.1007/s11094-022-02726-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-022-02726-8